CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
  • About
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

ViroCell Biologics and Great Ormond Street Hospital for Children Collaborate to Disrupt the Gene and Cell Therapy Industry

ViroCell Biologics and Great Ormond...

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural...

Genomics Market is anticipated to reach US$ 49,996.15 Mn by 2027

Genomics Market is anticipated to...

Bionano Genomics Symposium to feature OGM Presentations and Live Panel Discussion

Bionano Genomics Symposium to feature...

What is the Importance of Gene Editing in Farming?

What is the Importance of Gene...

Genome Editing: What Makes CRISPR-Cas9 a Preferred Choice?

Genome Editing: What Makes...

4 Diseases That Could Be Cured Using CRISPR Technology

4 Diseases That Could Be Cured Using...

Genome Editing Market: Development, Prospective and Regional Vision

Genome Editing Market: Development,...

ViroCell Biologics and Great Ormond Street Hospital for Children Collaborate to Disrupt the Gene and Cell Therapy Industry

ViroCell Biologics and Great Ormond...

Autolomous and Vineti to Establish a Fully Integrated End-To-End CGT Delivery Pathway Together

Life Sciences Review Life Sciences Review | Wednesday, November 10, 2021
Tweet

Vineti and Autolomous has formed a strategic agreement to provide end-to-end supply chain management solutions.


FREMONT, CA: “Autolomous is now building strategic value-add collaborations across the cell and gene therapy industry to provide solutions to critical needs within value chains. This will result in a holistic platform that specifically targets critical ecosystem partners, including healthcare providers, such as the UKs NHS, personalized therapy management platform providers including Vineti and those involved in the manufacturing component of supply chains, such as Autolomous,” states Alexander Seyf, CEO and Co-founder, Autolomous LTD. “We have selected to collaborate with Vineti to provide a unified single digital solution that can be used from the collection of patient starting material, manufacturing, through to the delivery of therapies. The seamless integration between Autolomous and VInetis solutions will ensure scalability when cell and gene therapies become standard of care, and involve a plethora of supply chain partners and patient samples.” Autolomous LTD, a world leader in essential production management systems for cell and gene treatments, and Vineti, a provider of market-leading digital enterprise platforms for cell and gene therapy supply chains, form a non-exclusive cooperation partnership.


“Partnering with Autolomous will allow Vineti to expand its provision across the CGT value chain. The integration of both organizations technologies will give Vineti additional tools to satisfy the rising procurement and delivery demands of the CGT sector,” comments Amy DuRoss, CEO and Co-founder, Vineti Inc. “Both companies are specialized within the heart of the CGT value chain and have delivered outputs that have made considerable and tangible cross-sector enhancements. The collaboration between Autolomous and Vineti will enable the provision of solutions required by the industry as it reaches a much larger scale.”


Autolomous' crucial manufacturing management systems will be integrated with Vinetis' Personalized Therapy Management® (PTM) platform as part of the agreement. This will enable both parties to establish a fully integrated end-to-end cell and gene therapy (CGT) delivery pathway, including crucial inbound and outbound manufacturing value processes. As a result, visibility and dynamic information flow between and among stakeholders throughout the cell & gene therapy value chain will rise. This enables them to respond to unforeseeable variables associated with biological process operations. Additionally, by boosting transparency, compliance, and auditability, the integration of technologies enables production to scale rapidly while also offering considerable time and resource savings through efficiency advantages.


Weekly Brief

loading
> <
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Regulatory Services 2022

    Top Vendors

    Current Issue
  • Clinical Stage Biopharmaceutical 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue
  • Clinical Trial Management 2022

    Top Vendors

    Current Issue

Read Also

Everything You Need to Know About Medical Lab Equipment and their Applications

Everything You Need to Know About Medical Lab Equipment and their Applications

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Lung Cancer patients can see improved results with Immunotherapy along with Chemotherapy Before surgery.

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks To Buy In 2022

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial

Efficacy and Safety Data by Entasis Therapeutics from Landmark Phase 3 Attack Trial
How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

The several benefits Of Agricultural Genome Editing

The several benefits Of Agricultural Genome Editing

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

2027 Might See a Market Growth of Third-party Logistics at a CAGR of 7.1 percent

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare

A Week To Celebrate The Significant Role Of Clinical Lab Professionals In Healthcare
Loading...

Copyright © 2022 Life Science Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/autolomous-and-vineti-to-establish-a-fully-integrated-endtoend-cgt-delivery-pathway-together-nwid-630.html